863971-52-2

Upstream product

• 55750-63-5 6-maleimidohexanoic acid N-hydroxylsuccinimide ester 
• 1258208-24-0 MeVal-citrulline-para-aminobenzyl-OH 
• 863971-51-1 Fmoc-MeVal-citrulline-para-aminobenzyl-OH 
• 103478-58-6 Fmoc-N-methylvaline 
• 863971-49-7 Fmoc-MeVal-OSu 
• 863971-50-0 Fmoc-MeVal-citrulline-COOH 
• 623-04-1 4-aminobenzenemethanol 

Relevant academic research and scientific papers

Monomethylvaline compounds conjugated with antibodies

Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.

MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS

Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The rlated conjugates can target specific cell types to provide therapeutic benefit.

MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE CARBOXY MODIFICATIONS AT THE C-TERMINUS

Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) having a carboxylic acid equivalent at the C-terminal phenylalanine were prepared and attached to ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.